Harry Gillis
Stock Analyst at Berenberg Bank
(4.49)
# 1,096
Out of 5,000 analysts
86
Total ratings
68.9%
Success rate
20.9%
Average return
Main Sectors:
Stocks Rated by Harry Gillis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Reiterated: Buy | $132 → $140 | $99.26 | +41.04% | 14 | Sep 15, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €270.00 → €280.00 | €265.30 | +5.54% | 7 | Sep 11, 2026 | |
| SWX: TECN Tecan Group AG | Reiterated: Buy | CHF 220.00 → CHF 240.00 | CHF 228.00 | +5.26% | 14 | Sep 10, 2026 | |
| MRNA Moderna | Reiterated: Hold | $45 → $100 | $194.82 | -48.67% | 13 | Sep 10, 2026 | |
| QGEN Qiagen | Reiterated: Hold | $46 | $44.56 | +2.11% | 11 | Sep 10, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Reiterated: Buy | kr 560.00 | kr 436.00 | +28.44% | 27 | Sep 10, 2026 |
BioNTech SE
Sep 15, 2026
Reiterated: Buy
Price Target: $132 → $140
Current: $99.26
Upside: +41.04%
Sartorius Aktiengesellschaft
Sep 11, 2026
Reiterated: Buy
Price Target: €270.00 → €280.00
Current: €265.30
Upside: +5.54%
Tecan Group AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 220.00 → CHF 240.00
Current: CHF 228.00
Upside: +5.26%
Moderna
Sep 10, 2026
Reiterated: Hold
Price Target: $45 → $100
Current: $194.82
Upside: -48.67%
Qiagen
Sep 10, 2026
Reiterated: Hold
Price Target: $46
Current: $44.56
Upside: +2.11%
Swedish Orphan Biovitrum AB (publ)
Sep 10, 2026
Reiterated: Buy
Price Target: kr 560.00
Current: kr 436.00
Upside: +28.44%